Publications

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

Publication Date: March 10, 2022

Abstract

Abstract Image

A critical unmet need for advanced prostate cancer (PCa) patients is optimizing systemic treatments to maximize the benefit for individuals. The response of patients with metastatic castration-resistant prostate cancer (mCRPC) to androgen receptor (AR)-directed hormonal treatments (i.e., enzalutamide and abiraterone) is mediated by the expression of a molecular variant of the androgen receptor called androgen receptor variant 7 (AR-V7). Detection and measurement of AR-V7 in mCRPC patients will lead to more informed PCa treatment. Herein, we demonstrate a quantitative nanoparticle-enhanced sandwich antibody assay for the successful ex vivo measurement of AR-V7 protein in serum from mCRPC patients. The nanoparticles are constructed as extrinsic Raman spectroscopy labels (ERLs), and surface-enhanced Raman spectroscopy (SERS) is used for assay readout. Our approach does not require specialized specimen collection materials, circulating tumor cell enrichment, or pretreatment of serum. Calibration of our assay is accomplished by expressing AR-V7 in an appropriate cell line as AR-V7 is not commercially available. We demonstrate a linear calibration curve from cell lysate and correlate lysate protein with mRNA from cultured prostate cancer cells. Finally, we demonstrate a novel pilot-scale application for clinical use by quantitatively measuring AR-V7 in serum of seven advanced PCa patients. Distinct separation of PCa patients by AR-V7 status (positive or negative) was observed. Together, the presence and amount of AR-V7 in serum offer predictive and prognostic value to inform selection between two classes of systemic treatments (i.e., hormones or taxanes). Triaging patients that are AR-V7-positive to other systemic treatments (e.g., taxane-based chemotherapy) can improve progression-free survival and overall survival.

Cite this: ACS Sens. 2022

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

We are excited to announce the recent online publication of PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks in the Journal of Clinical Oncology-Clinical Cancer Informatics!

PROSPeCT is a user-friendly online clinical information system that offers an easy and efficient way to obtain relevant and accurate information about patients from APCaRIs robust and expanding database. If you use PROSPeCT already then please cite this article in your work. If you do not use PROSPeCT yet then read this article for more details about easy-to-use and powerful query tool! Thank you to the Alberta Cancer Foundation, plus others, for supporting this project.

Citation
PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks
Maria Cutumisu, Catalina Vasquez, Maxwell Uhlich, Perrin H. Beatty, Homeira Hamayeli-Mehrabani, Rume Djebah, Albert Murtha, Russell Greiner, and John D. Lewis
JCO Clinical Cancer Informatics 2019 :3, 1-12 DOI: 10.1200/CCI.18.00144

2019.05 Cutumisu et al PROSPeCT JCO CCI

- Unknown